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Abstract
Succinate dehydrogenase (SDH) is an enzyme complex, composed of four protein subunits, that plays a role in both the citric acid
cycle and the electron transport chain. The genes for SDHA, SDHB, SDHC, and SDHD are located in the nuclear DNA, and
mutations in these genes have initially been described in paragangliomas (PGL) and pheochromocytomas (PCC), which are
relatively rare tumors derived from the autonomic nervous system and the adrenal medulla, respectively. Patients with SDH
mutations, that are almost exclusively in the germline, are frequently affected by multiple PGL and/or PCC. In addition, other
tumors have been associated with SDH mutations as well, including gastrointestinal stromal tumors, SDH-deficient renal cell
carcinoma, and pituitary adenomas. Immunohistochemistry for SDHB and SDHA has been shown to be a valuable additional
tool in the histopathological analysis of these tumors, and can be considered as a surrogate marker for molecular analysis. In
addition, SDHB immunohistochemistry is relevant in the decision-making whether a genetic sequence variant represents a
pathogenic mutation or not. In this review, we highlight the current knowledge of the physiologic and pathologic role of the
SDH enzyme complex and its involvement in endocrine and non-endocrine tumors, with an emphasis on the applicability of
immunohistochemistry.
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SDH Complex: Genes, Proteins, Function
Structure and Assembly
Succinate dehydrogenase (SDH) is a unique protein complex,
being part of the citric acid cycle and playing a role in the
mitochondrial respiratory chain. SDH activity was first detect-
ed in 1909 [1]. SDH consists of two hydrophilic proteins and
two hydrophobic proteins. The hydrophilic proteins are SDH
subunit A (SDHA), a flavoprotein containing an FAD cofactor
and the binding site for succinate, and SDH subunit B
(SDHB), an iron-sulfur protein with three FeS clusters. The
two hydrophobic proteins SDH subunits C and D (SDHC and
SDHD) are transmembrane proteins that contain a bound
heme and a binding site for ubiquinone (Fig. 1) [2]. All
SDH subunits are encoded by nuclear genes. This is in con-
trast to all other oxidative phosphorylation complexes, of
which the proteins are encoded by the mitochondrial genome
(https://www.genecards.org). The gene details of the four
SDH genes are listed in Fig. 1.
The correct assembly of the SDH complex relies on so-
called assembly factors. Currently, at least four of these have
been described. Of these, SDH assembly factor 1 and 2
(SDHAF1 and SDHAF2) are the best studied ones.
SDHAF1 is a soluble protein, but is not a stable component
of the SDH complex. Data suggests that SDHAF1 is impor-
tant for the insertion or retention of the Fe-S centers within
SDH [3]. Yeast mutants lacking SDHAF1 showed only a 60–
70% decrease in SDH activity and not a complete loss of
function, rendering the possibility that other (unknown) as-
sembly factors are involved as well [4].
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SDHAF2 is also a soluble protein of 166 amino acids,
encoded by the SDHAF2 gene. Yeast mutants for SDHAF2
showed undetectable SDH activity, while the activity of other
citric acid cycle enzymes and electron transport chain com-
plexes was normal. SDHAF2 seems to be required for the
covalent insertion of FAD into SDHA [5]. The role of
SDHAF2 in relation to pheochromocytoma (PCC) and
paraganglioma (PGL) is discussed below, in the paragraph
on SDH genes in PCC and PGL.
Very recently, a variant in SDHAF3 (c.157 T>C
[p.Phe53Leu]) has been associated with an increased preva-
lence of PCC and/or PGL. However, the exact meaning for the
genesis of PCC and PGL is still unclear and further research is
needed [6].
For SDHAF4, no direct link with tumorigenesis has been
described so far. However, in SDHAF4 knockout cells, a de-
creased SDH enzymatic activity is seen and it was concluded
that SDHAF4 is required for the proper assembly and activity
of the SDH complex. In Drosophila, a proper functioning of
SDHAF4 is critical for preventing motility defects and neuro-
degeneration [7].
Function
The SDH complex is situated at the crossroads of the mito-
chondrial respiratory chain and the citric acid cycle (which is
also known as the tricarboxylic acid cycle or Krebs cycle).
The citric acid cycle which was identified in 1937 by Hans
Adolf Krebs is a process that oxidizes glucose derivatives
through a series of enzyme-controlled steps [8]. During these
steps, high-energy electrons are collected, which are
transported by the activated carriers NADH and FADH2 to
the electron transport chain. The first step is not really part of
the citric acid cycle, but it links glycolysis to the citric acid
cycle. In step 6 of the citric acid cycle, SDH catalyzes the
oxidation of succinate to fumarate with the reduction of ubi-
quinone to ubiquinol.
In the mitochondrial respiratory chain, there are four large
membrane protein complexes in the inner mitochondrial mem-
brane, including Complex I (NADH: ubiquinone oxidoreduc-
tase), complex II (SDH), complex III (cytochrome c reductase),
and complex IV (cytochrome c oxidase). The SDH complex is
the only of the four complexes that does not function as a proton
pump. Instead, SDH contributes additional electrons to ubiqui-
none that originates from succinate [9]. During these steps, an
electrochemical proton gradient is created that drives the syn-
thesis of ATP, of which huge amounts are needed in the eukary-
otic cell for proper cell functioning. The functional role of the
SDH complex is relevant in case of its disturbance bymutations
in any of the composing proteins as will be discussed later.
Detection of SDH Gene Mutations in Human
Disease
SDH in Neurodegenerative Disorders
As can be inferred from the previous paragraph, SDH muta-
tions cause mitochondrial dysfunction. Tissues with high en-
ergy demand (heart, skeletal muscle, and the central nervous
system) are most vulnerable to this [10]. SDHA mutations
have been described as a rare cause of Leigh syndrome or
subacute necrotizing encephalomyelopathy [11]. Leigh syn-
drome is a lethal, autosomal recessive progressive neurode-
generative disorder of childhood. The syndrome consists of
focal, bilateral lesions in the basal ganglia, thalamus, cerebel-
lum, and/or spinal cord [10]. Partial SDHA deficiency (resid-
ual activity > 50%) has been described in two sisters and
caused late onset optic atrophy, ataxia, and myopathy [12].
In addition, autosomal recessive SDHA mutations have been
described in a family with neonatal isolated dilated
Fig. 1 Schematic structure of the
SDH complex localized in the
inner mitochondrial membrane.
The table on the left gives an
overview of the number of amino
acids (Aa), chromosome (Chr.)
location, and number of exons of
each of the SDH genes
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cardiomyopathy [13]. In 2009, homozygous SDHAF1 muta-
tions were found in children of a Turkish and an Italian family
with SDH-defective infantile leukoencephalopathy [4]. Also,
mutations in SDHB and SDHD have been found to cause
Leigh syndrome [14, 15].
SDH Genes in PCC and PGL, SDH Syndrome
It is now known that in about 40% of hereditary PCC/PGL SDH
germline mutations can be found. In sporadic cases, the preva-
lence of SDH germline mutations is up to 15% [16–18]. In 2000,
SDHD was the first SDH gene demonstrated to be associated
with familial PGL type 1 (PGL1) [19]. Subsequently, other SDH
genes were found to be PCC/PGL susceptibility genes, and
germline mutations of SDHAF2, SDHC, SDHB, and SDHA are
associated with the familial syndromes PGL2 to PGL5, respec-
tively [5, 20–22]. These syndromes are autosomal dominant,
with maternal imprinting effects for SDHD and SDHAF2 [23,
24]. In patients with germline SDHD or SDHAF2 mutations,
tumors develop almost exclusively if mutations are inherited
via the paternal line. Both genes are located on the long arm of
chromosome 11. It has been shown that in SDHD-mutated PGL,
loss of the entire maternal copy of chromosome 11 occurs. Since
neither SDHD nor SDHAF2 is imprinted, other genes that are
exclusively maternally expressed should play a role in tumor
development. This phenomenon is now known as the Hensen
Model [25, 26].
The penetrance of tumor development in patients with SDH
mutations is highly variable, being high for SDHD (87–100%)
and much lower for SDHB (25–40%) [27]. In 2018, Rijken
et al. found an estimated SDHB-linked penetrance of 21% at
age 50 [28]. SDHD mutations predispose to multifocal head
and neck PGL and less commonly to non-metastatic abdominal
PGL or PCC [29]. SDHAF2mutations are rare; only four PGL2
families have been described, often with multifocal, but non-
metastatic head and neck PGL [30]. Germline SDHCmutations
are found in around 4% of head and neck PGL, usually non-
metastatic carotid body PGL [31]. SDHB-mutated tumors are
mostly extra-adrenal PGL and are associated with a high met-
astatic potential of up to 50% [32]. Head and neck PGL occur
in 20–30% of SDHB-mutation carriers [33]. SDHA mutations
are rare and demonstrate a low penetrance, accounting for only
3% of PCC/PGL [34]. Importantly, SDH mutations have been
associated with other disorders and solid tumors, which will be
discussed hereafter. An overview of SDH genes and tumor
associations of PCC/PGL is shown in Table 1.
SDH Genes in Other Tumors
SDH-Deficient Gastrointestinal Stromal Tumor
Most gastrointestinal stromal tumors (GIST) occurring in
adults result from gain of function gene mutations of KIT
(75–80% of the cases) or PDGFRA (5–25%) [35]. The re-
maining 10% of adult GIST, and about 85% of pediatric
GIST are non-KIT/PDGFRA-mutated tumors, so-called wild-
type GIST. The latter group can be classified into SDH-
deficient and non-SDH-deficient cases (including tumors with
mutations in NF1, BRAF, KRAS, PIK3CA, or containing the
ETV6-NTRK3 fusion) [36]. SDH-deficient GIST are now be-
ing recognized as a distinct class of tumors with specific
clinico-pathological features compared to non-SDH-deficient
GIST. These tumors arise in the stomach, are more common in
children and young adults and show a female predisposition.
Histopathologically, they are multifocal, demonstrating a
multinodular, lobulated growth pattern composed of predom-
inantly epithelioid cells [37]. Even though lymph node metas-
tases are frequently present, their behavior is commonly indo-
lent. In contrast toKIT/PDGRA-mutated GIST, SDH-deficient
GIST do not respond to therapy with Imatinib [37, 38]. About
5–10% of all gastric GIST are SDH-deficient, in which SDHA
mutations are most commonly identified (30%), while up to
20% are associated with SDHB, SDHC, or SDHD mutations.
The remaining 50% is associated with SDHC epimutations
resulting in promoter hypermethylation [38]. SDHC
epimutation has also been reported in patients with Carney
triad [39, 40]. In this very rare, non-familial syndrome mostly
affecting young females, SDH-deficient GIST are associated
with PGL and pulmonary chondromas [41]. Tumors from
patients with Carney triad do not harbor SDH gene mutations,
but SDH deficiency results from SDHC promoter-specific
CpG island hypermethylation and subsequent gene silencing.
A related disease is Carney-Stratakis syndrome, the familial
dyad of PGL and GIST affecting both young males and fe-
males. Carney-Stratakis syndrome is inherited as an autoso-
mal dominant trait in which germline mutations in SDHB,
SDHC, and SDHD can be identified. PGL are the predominant
manifestation in Carney-Stratakis syndrome, while GIST are
predominant in Carney Triad [41, 42].
SDH-Deficient Renal Cell Carcinoma
SDH-deficient renal cell carcinomas (RCC) account for 0.05–
0.2% of all RCCs [43]. SDHB-mutated patients affected by
RCC were reported for the first time in 2004 [44]. Similar to
SDH-deficient GIST, SDH-deficient RCC show distinctive
clinico-pathological characteristics. Therefore, they are cur-
rently being recognized as a distinct type of RCC in the
2016 WHO classification of renal tumors [45]. The mean
age at presentation is 38 years, with a slight male predomi-
nance. Multifocal or bilateral tumors are detected in 30% of
patients at long-term follow-up, and the risk of metastasis is
low (estimated at 11%) [45]. Most SDH-deficient RCC show
distinctive histologic features with the presence of cytoplas-
mic vacuoles and inclusion-like spaces containing eosinophil-
ic or flocculent material [43]. However, variant morphologies
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have been reported. SDH-deficient RCC are most commonly
due to SDHB mutations. In SDHB mutation carriers, the risk
of RCC by age 60 years is 4.7% [33]. However, RCC can also
occur in SDHC and SDHD mutation carriers (in 14% and 8%
of patients, respectively), in addition to one case of SDHA-
deficient RCC [38, 46].
SDH-Deficient Pituitary Adenoma
The combination of pituitary adenomas (PA) with PCC or
PGL (termed B3Pas^) is very rare and can either be coinciden-
tal or the result of a common pathogenesis [47]. In 2012, an
SDH-related PAwas described for the first time in an SDHD
mutation carrier with multiple head and neck, thoracic and
abdominal PGL [48]. In the subsequent year, another SDHA-
related PAwas described [49]. To date, about 25 patients with
SDH-related PA have been described with SDHA, SDHB,
SDHC, SDHD, or SDHAF2 mutations [50]. These tumors
are most often prolactin- or growth hormone-producing
macroadenomas with varying ages at diagnosis, ranging from
15 to 84 years [36]. Some authors report vacuolated, clear
cytoplasm as a hallmark of SDH-mutated PA, reminiscent of
that seen in SDH-deficient RCC [47]. However, others could
not identify distinctive morphologic features [38, 49].
Recently, a pituitary carcinoma has been described in a female
patient with an SDHB mutation and a history of glomus PGL
[51].
Other SDH-Deficient Tumors
Even though other tumors than GIST, RCC, and PA have been
reported in PCC/PGL patients with germline SDH mutations,
very few of these have been proven to be related to SDH
deficiency. Ni et al. investigated the occurrence of both
germline and somatic SDH mutations/variations in 754 cases
of differentiated thyroid carcinoma [52]. They found germline
SDH missense variants in 48 (6%; 26 SDHD and 22 SDHB)
patients. In addition, they found large somatic duplications
within chromosome 1 encompassing SDHC in 27 of 513 tu-
mors (5%) [52]. Furthermore, both papillary and follicular
thyroid tumors showed a significant reduction in SDHC and
SDHDmRNA expression compared to normal thyroid tissues.
Thyroid tumors with lower SDH gene expression were asso-
ciated with an earlier age at diagnosis and a high pathological-
TNM stage [52]. However, the link between pathogenic SDH
mutations and thyroid carcinogenesis remains to be
established [53, 54]. To the best of our knowledge, to date,
no SDHB immunonegative thyroid carcinoma has been
described.
In 2015, an SDH-deficient low-grade pancreatic neuroen-
docrine tumor has been described in a patient with a germline
SDHD mutation with multiple head and neck PGL and an
oligodendroglioma in the frontal lobe [50]. The tumor was
immunonegative for SDHB, immunopositive for SDHA,
and showed loss of the wild-type SDHD allele. However,
others postulate that this single case may be better classified
as an intrapancreatic PGL [38]. Scarpa et al. did not find any
pathogenic SDH mutations in102 primary pancreatic neuro-
endocrine tumors after whole genome sequencing [55].
Pópulo et al. analyzed SDHD promoter mutations in 86 cuta-
neous melanomas and found alterations in 2 (2%) of the cases
[56]. They also evaluated SDHD protein expression in 107 cu-
taneous melanomas. A low staining score and a moderate/high
staining score was observed in 41% and 59% of the tumors,
respectively. Moreover, a significant association was found be-
tween lower mean SDHD protein expression and the presence of
ulceration and higher pathological-Tstage [56]. SDHDmutations
might be associated with prognosis of cutaneous melanoma, but
are not proven to be related to tumorigenesis.
Many other tumors including adrenal neuroblastoma, bron-
chial carcinoid, ependymoma, Hodgkin lymphoma, and colon
cancer have been described in SDH mutation carriers or their
relatives [57]. Up to now, no support has been found for a
pathogenetic association of any of these tumors with the pres-
ence of SDH mutations.
SDH Immunohistochemistry
In the rapidly expanding field of molecular genetic testing, it is
important to assess the pathogenicity of identified SDH
Bvariants of unknown significance^ [58]. SDHB and SDHA
immunohistochemistry can be used as a quick, reliable, and
Table 1 SDH genes and tumor
associations of PCC and PGL Gene PCC sPGL HNPGL Penetrance Metastatic potential Other tumors
SDHD x x xx 87–100% Up to 4% GIST, RCC, PA
SDHB x xx x 25–40% Up to 50% GIST, RCC, PA
SDHC x xx Low 0% GIST, RCC, PA
SDHAF2 x Not known 0% PA
SDHA x x xx Very low Not known GIST, PA, RCC
PCC pheochromocytoma, sPGL sympathetic paraganglioma, HNPGL head and neck paraganglioma, GIST
gastrointestinal stromal tumor, RCC renal cell carcinoma, PA pituitary adenoma
Endocr Pathol
cheap tool to determine the functionality of such genetic var-
iants. Normally, SDHB and SDHA staining is positive in all
cells, with strong granular and cytoplasmic labeling
representing mitochondrial localization of the protein [59].
In tumors, non-tumoral cells such as endothelial cells, fibro-
blasts, or lymphocytes can be used as an internal positive
control. If any of the subunits of the SDH complex is lost
due to (epi) mutation, the entire complex becomes unstable
and the SDHB subunit is degraded in the cytoplasm [60]. This
loss of the SDHB protein can be shown by SDHB immuno-
histochemistry (Figs. 2 and 3c–d) [59]. Tumors with
inactivating SDHA, SDHB, SDHC, SDHD, or SDHAF2 mu-
tations demonstrate loss of cytoplasmic SDHB staining. If
SDHB staining in the tumor cells is evidently less intense
compared to non-tumoral cells, or if it shows a weak diffuse
cytoplasmic blush instead of a granular staining pattern,
SDHB immunohistochemistry should be regarded negative
[38]. Of note, SDHB immunostaining might appear falsely
negative in tumor areas with clear cytoplasm, for example in
clear cell RCC. In such cases, the best approach is to look for
areas with eosinophilic cytoplasm for interpretation of the
staining. In a multicenter study, SDHB immunohistochemis-
try was shown to be a robust technique with almost 90%
consensus in a group of seven reviewers. The positive and
negative predictive value of the seven reviewers of SDHB
immunohistochemistry to detect SDH mutations ranged from
67 to 93%, and from 90 to 99%, respectively [58].
In addition, SDHA immunohistochemistry was proven to
be a useful marker to detect tumors with SDHA mutations, as
is the case in tumors with pathogenic SDHAmutations togeth-
er with second hit inactivation [34]. SDHA cytoplasmic stain-
ing is negative in SDHA-mutated tumors, while tumors with
mutations in any of the other SDH subunits show preserved
SDHA staining (Fig. 3a–b). These findings suggest that the
SDHB protein is degraded when the SDH complex is
disrupted, whereas the SDHA protein remains intact [34]. Of
note, SDHA mutations may be present in up to 0.3% of the
general population, as these mutations have a low, incomplete
penetrance pattern [34, 38].
Molecular genetic testing is labor intensive and requires
clinical molecular diagnostic laboratories, so SDHB and
SDHA immunohistochemistry can be used as a supplemen-
tary tool to identify patients with SDH-deficient tumors. As
has been mentioned above, some tumors show a weak dif-
fuse cytoplasmic SDHB immunostain, particularly PCC/
PGL with SDHD mutations [38]. Therefore, Menara et al.
evaluated in 170 PCC/PGL if SDHD immunohistochemis-
try could be used to detect SDHD mutations [60].
Interestingly, they showed that SDHD immunostaining is
positive in SDH-deficient tumors and negative in SDH
wild-type tumors. A possible explanation for this paradoxal
result is that the SDHD epitope is masked in the transmem-
brane domain of the protein in the normal state, but that
disruption of the SDH complex releases the epitope, making
it accessible for immunostaining [61]. Even though SDHD
immunohistochemistry cannot be used to specifically detect
SDHD-mutated tumors, the staining provides a complement
to difficult to interpret SDHB immunostainings. Weak
Fig. 2 a Positive SDHB
immunostaining in a non-SDH-
related PGL demonstrating strong
granular (mitochondrial)
cytoplasmic staining, b negative
SDHB immunostaining in an
SDH-mutated PGL
demonstrating absent SDHB
staining in tumor cells.
Endothelial cells serve as internal
positive controls and show
positive SDHB staining, c & d
weak diffuse (in contrast to
granular) cytoplasmic SDHB
staining in two SDH-related PGL.
The staining of the endothelial
cells is more intense dark brown
and granular, meaning that the
tumor cells should be scored as
SDHB negative
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diffuse or discordant negative cytoplasmic SDHB staining
has also been described in a minor subset of VHL- and NF1-
mutated PCC/PGL. Therefore, if SDH genetic testing of an
SDHB-immunonegative tumor does not show a mutation,
SDHC promoter methylation, VHL, and/or NF1 molecular
testing is recommendable [58].
Tumorigenic Mechanism of SDH Abnormalities
As described above, SDH mutations are commonly observed
in a number of hereditary and sporadic malignancies.
Mutations in any of the four SDH subunits lead to the disin-
tegration of the SDH complex and result in a complete loss of
SDH enzymatic activity [62]. Dysfunction of SDH can lead to
succinate accumulation and a low level of fumarate. The ac-
cumulation of succinate promotes angiogenesis by activation
of the hypoxia-inducible factor (HIF) pathway, as has been
shown in gene expression analysis. In that study, SDHB-,
SDHD- or VHL-mutated PCC revealed a gene expression pat-
tern with a BHIF signature^ [63]. In addition, Selak et al.
showed that SDH dysfunction increased succinate levels, first
accumulating in the mitochondrial matrix and subsequently
leaking into the cytosol where it inhibits the activity of prolyl
hydroxylases, leading to HIFa stabilization and activation of
the HIF pathway [64]. Another explanation for the stabiliza-
tion of HIF-1α in SDH-deficient tumors is the generation of
reactive oxygen species (ROS). Although SDH is not consid-
ered a major site for ROS production in the electron transport
chain under normal conditions, in PCC and PGL, evidence of
an association between SDH mutations and oxidative stress is
present [65].
Tumors in the Context of Other Citric Acid Cycle Gene
Mutations
Apart from SDH, other citric acid cycle enzymes have been
shown to be mutated or deregulated in various types of tu-
mors. Isocitrate dehydrogenase (IDH), comprised of three iso-
forms (IDH1, IDH2, and IDH3), converts isocitrate to α-
ketoglutarate. IDH1 and IDH2mutations are frequently found
in low-grade gliomas and in secondary glioblastomas.
Mutations have also been described in acute myeloid leuke-
mia and T cell lymphomas [66, 67]. IDH mutations may also
occur in PGL, but are rare [68]. They result in increased con-
version of α-ketoglutarate to 2-hydroxyglutarate (2-HG),
leading to accumulation of 2-HG. This occurs in the brain of
patients with 2-hydroxyglutarate dehydrogenase deficiency,
who go on to develop leukoencephalopathy, and have an in-
creased risk of developing brain tumors [69, 70].
Fumarate hydratase (FH) catalyzes the hydration of fuma-
rate to L-malate. FH mutations are classically found in hered-
itary leiomyomatosis and renal cell cancer, where patients
may present with multiple cutaneous leiomyomas and a spe-
cific RCC subtype. Similar to SDH-mutated tumors, FH-mu-
tated tumors display upregulation of HIF [71]. FH-deficient
cells show inhibition of HIF-1α prolyl hydroxylation by ac-
cumulated intracellular fumarate. FH mutations have also
been found in PCC and PGL, and FH-deficient tumors may
Fig. 3 a Positive granular SDHA
immunostaining in a non-SDH-
related GIST, b absence of SDHA
immunostaining in the tumor cells
of an SDHA-mutated GIST. In
contrast, staining is positive in
endothelial cells that serve as
internal positive control, c
positive SDHB immunostaining
in a non-SDH-related clear cell
RCC, d negative SDHB
immunostaining in an SDH-
deficient RCC
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be detected by immunohistochemistry through their nuclear
and cytoplasmic staining of 2SC and the absence of FH im-
munostaining [72, 73].
Malate dehydrogenase (MDH) is an enzyme that catalyzes
the oxidation of malate to oxaloacetate using the reduction of
NAD+ to NADH. There are two known isoforms. One iso-
form is a principal enzyme of the citric acid cycle operating
within mitochondria. The other is found in the cytosol where it
participates in the malate/aspartate shuttle. Cascon et al. de-
scribed a PGL family carrying a germline mutation inMDH2.
These tumors showed lower levels of MDH2 expression com-
pared with control patients. In addition, knockdown ofMDH2
in HeLa cells showed accumulation of both malate and fuma-
rate [74]. MDH1 mutations are associated with retinitis
pigmentosa, sideroblastic anemia, and spinocerebellar ataxia
[75].
In addition to mutations detected in genes coding for citric
acid cycle enzymes, several studies have demonstrated
deregulated enzymes (e.g., a-ketoglutarate dehydrogenase,
citrate synthase, Acetyl-coenzyme A carboxylase) in other
cancer types, including colorectal, pancreatic, ovarian, renal,
gastric, and prostate cancer [76–78].
Conclusions
The SDH complex is a biologically and biochemically
fascinating enzyme complex, composed of four subunits,
that has a pivotal role in both citric acid cycle and elec-
tron transport chain. Over the last two decades, we have
discovered its crucial role in the pathogenesis of PCC,
PGL, and several other tumor types, mostly in a heredi-
tary setting. Immunohistochemistry for SDHB and SDHA
has obtained an important place in diagnostic pathology
for the recognition of any SDH-related tumor and has
become a well-established surrogate marker for molecular
analysis and for confirmation of genetic variants of un-
known significance. The current challenges are as fol-
lows: (1) to elaborate on such immunohistochemical
markers in other areas of pathology [79]; (2) to detect
genetic abnormalities in related genetic sequences (pro-
moter regions, intron/exon boundaries) or genes (SDH
assembly factors, other citric acid cycle genes); (3) to
use the increasing knowledge on the functional conse-
quences of loss of enzymatic activity for the development
of therapeutic interventions that may affect or prevent
tumor development.
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